Gwendolyn Gresham - 31 Dec 2025 Form 4 Insider Report for Core Laboratories Inc. /DE/ (CLB)

Role
SVP
Signature
/s/ Mark Tattoli, Attorney-in-Fact
Issuer symbol
CLB
Transactions as of
31 Dec 2025
Net transactions value
-$309,395
Form type
4
Filing time
05 Jan 2026, 15:18:06 UTC
Previous filing
13 Feb 2025
Next filing
17 Feb 2026

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Gresham Gwendolyn SVP 6316 WINDFERN ROAD, HOUSTON /s/ Mark Tattoli, Attorney-in-Fact 05 Jan 2026 0001842114

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CLB Common Stock Tax liability $309,395 -19,301 -37% $16.03 33,226 31 Dec 2025 Direct
transaction CLB Common Stock Options Exercise $0 +24,952 +90% $0.000000 52,527 31 Dec 2025 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CLB Performance Shares Options Exercise $0 -24,952 -100% $0.000000 0 31 Dec 2025 Common Stock 24,952 $0.000000 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These shares were awarded as restricted performance shares in February 2023, as disclosed in the Reporting Person's Form 4 filing on February 21, 2023. The Company finished in the 68th percentile of return on invested capital among the Bloomberg Peer Group at the conclusion of the performance period on December 31, 2025. Therefore, the performance criteria and requirements for vesting have been satisfied at 116.5% of the target award level, and such number of shares vested on December 31, 2025.